COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
Autoři
BUSCA, Alessandro (garant), Jon SALMANTON-GARCÍA, Paolo CORRADINI, Francesco MARCHESI, Alba CABIRTA, Roberta Di BLASI, Remy DULERY, Sylvain LAMURE, Francesca FARINA, Barbora WEINBERGEROVÁ (203 Česká republika, domácí), Josip BATINIĆ, Anna NORDLANDER, Alberto LÓPEZ-GARCÍA, Ľuboš DRGOŇA, Ildefonso ESPIGADO-TOCINO, Iker FALCES-ROMERO, Ramón GARCÍA-SANZ, Carolina GARCÍA-VIDAL, Anna GUIDETTI, Nina KHANNA, Austin KULASEKARARAJ, Johan MAERTENS, Martin HOENIGL, Nikolai KLIMKO, Philipp KOEHLER, Antonio PAGLIUCA, Francesco PASSAMONTI, Oliver A CORNELY a Livio PAGANO
The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.
BUSCA, Alessandro, Jon SALMANTON-GARCÍA, Paolo CORRADINI, Francesco MARCHESI, Alba CABIRTA, Roberta Di BLASI, Remy DULERY, Sylvain LAMURE, Francesca FARINA, Barbora WEINBERGEROVÁ, Josip BATINIĆ, Anna NORDLANDER, Alberto LÓPEZ-GARCÍA, Ľuboš DRGOŇA, Ildefonso ESPIGADO-TOCINO, Iker FALCES-ROMERO, Ramón GARCÍA-SANZ, Carolina GARCÍA-VIDAL, Anna GUIDETTI, Nina KHANNA, Austin KULASEKARARAJ, Johan MAERTENS, Martin HOENIGL, Nikolai KLIMKO, Philipp KOEHLER, Antonio PAGLIUCA, Francesco PASSAMONTI, Oliver A CORNELY a Livio PAGANO. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood advances. AMSTERDAM: ELSEVIER, 2022, roč. 6, č. 7, s. 2427-2433. ISSN 2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2021005616.
@article{2262319, author = {Busca, Alessandro and SalmantonandGarcía, Jon and Corradini, Paolo and Marchesi, Francesco and Cabirta, Alba and Blasi, Roberta Di and Dulery, Remy and Lamure, Sylvain and Farina, Francesca and Weinbergerová, Barbora and Batinić, Josip and Nordlander, Anna and LópezandGarcía, Alberto and Drgoňa, Ľuboš and EspigadoandTocino, Ildefonso and FalcesandRomero, Iker and GarcíaandSanz, Ramón and GarcíaandVidal, Carolina and Guidetti, Anna and Khanna, Nina and Kulasekararaj, Austin and Maertens, Johan and Hoenigl, Martin and Klimko, Nikolai and Koehler, Philipp and Pagliuca, Antonio and Passamonti, Francesco and Cornely, Oliver A and Pagano, Livio}, article_location = {AMSTERDAM}, article_number = {7}, doi = {http://dx.doi.org/10.1182/bloodadvances.2021005616}, keywords = {Clinical Trials and Observations; Immunobiology and Immunotherapy; Stimulus Report}, language = {eng}, issn = {2473-9529}, journal = {Blood advances}, title = {COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP}, url = {https://ashpublications.org/bloodadvances/article/6/7/2427/477883/COVID-19-and-CAR-T-cells-a-report-on-current}, volume = {6}, year = {2022} }
TY - JOUR ID - 2262319 AU - Busca, Alessandro - Salmanton-García, Jon - Corradini, Paolo - Marchesi, Francesco - Cabirta, Alba - Blasi, Roberta Di - Dulery, Remy - Lamure, Sylvain - Farina, Francesca - Weinbergerová, Barbora - Batinić, Josip - Nordlander, Anna - López-García, Alberto - Drgoňa, Ľuboš - Espigado-Tocino, Ildefonso - Falces-Romero, Iker - García-Sanz, Ramón - García-Vidal, Carolina - Guidetti, Anna - Khanna, Nina - Kulasekararaj, Austin - Maertens, Johan - Hoenigl, Martin - Klimko, Nikolai - Koehler, Philipp - Pagliuca, Antonio - Passamonti, Francesco - Cornely, Oliver A - Pagano, Livio PY - 2022 TI - COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP JF - Blood advances VL - 6 IS - 7 SP - 2427-2433 EP - 2427-2433 PB - ELSEVIER SN - 24739529 KW - Clinical Trials and Observations KW - Immunobiology and Immunotherapy KW - Stimulus Report UR - https://ashpublications.org/bloodadvances/article/6/7/2427/477883/COVID-19-and-CAR-T-cells-a-report-on-current N2 - The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients. ER -
BUSCA, Alessandro, Jon SALMANTON-GARCÍA, Paolo CORRADINI, Francesco MARCHESI, Alba CABIRTA, Roberta Di BLASI, Remy DULERY, Sylvain LAMURE, Francesca FARINA, Barbora WEINBERGEROVÁ, Josip BATINI$\backslash$'C, Anna NORDLANDER, Alberto LÓPEZ-GARCÍA, Ľuboš DRGOŇA, Ildefonso ESPIGADO-TOCINO, Iker FALCES-ROMERO, Ramón GARCÍA-SANZ, Carolina GARCÍA-VIDAL, Anna GUIDETTI, Nina KHANNA, Austin KULASEKARARAJ, Johan MAERTENS, Martin HOENIGL, Nikolai KLIMKO, Philipp KOEHLER, Antonio PAGLIUCA, Francesco PASSAMONTI, Oliver A CORNELY a Livio PAGANO. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. \textit{Blood advances}. AMSTERDAM: ELSEVIER, 2022, roč.~6, č.~7, s.~2427-2433. ISSN~2473-9529. Dostupné z: https://dx.doi.org/10.1182/bloodadvances.2021005616.